ArticleParasitology research2004
A novel Cryptosporidium parvum antigen, CP2, preferentially associates with membranous structures.
Article in Parasitology research, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- Article
- Specific Cryptosporidium antigens associate with reinfection immunity and protection from cryptosporidiosis.The Journal of clinical investigation · 2023Article
- Cryptosporidiosis: From Prevention to Treatment, a Narrative Review.Microorganisms · 2022Review
- Alterations in oxidative stress parameters and its associated correlation with clinical disease on experimentalJournal of parasitic diseases : official organ of the Indian Society for Parasitology · 2017Article
- Evolution of mitosome metabolism and invasion-related proteins in Cryptosporidium.BMC genomics · 2016Article
- Cryptosporidium hominis gene catalog: a resource for the selection of novel Cryptosporidium vaccine candidates.Database : the journal of biological databases and curation · 2016Article
- A nanotherapy strategy significantly enhances anticryptosporidial activity of an inhibitor of bifunctional thymidylate synthase-dihydrofolate reductase from Cryptosporidium.Bioorganic & medicinal chemistry letters · 2015Article
- Cryptosporidium pathogenicity and virulence.Clinical microbiology reviews · 2013Review
- TLR4 promotes Cryptosporidium parvum clearance in a mouse model of biliary cryptosporidiosis.The Journal of parasitology · 2011Article
- The cell biology of cryptosporidium infection.Microbes and infection · 2011Review
- Cholangiocyte myosin IIB is required for localized aggregation of sodium glucose cotransporter 1 to sites of Cryptosporidium parvum cellular invasion and facilitates parasite internalization.Infection and immunity · 2010Article
- HIV-1 Tat protein suppresses cholangiocyte toll-like receptor 4 expression and defense against Cryptosporidium parvum.The Journal of infectious diseases · 2009Article
- Pulsed-UV light inactivation of Cryptosporidium parvum.Parasitology research · 2008Article
- CP2 gene as a useful viability marker for Cryptosporidium parvum.Parasitology research · 2008Article
- The human immunodeficiency virus type 1 tat protein enhances Cryptosporidium parvum-induced apoptosis in cholangiocytes via a Fas ligand-dependent mechanism.Infection and immunity · 2007Article
- Accumulation of tropomyosin isoform 5 at the infection sites of host cells during Cryptosporidium invasion.Parasitology research · 2006Article
- Apical organelle discharge by Cryptosporidium parvum is temperature, cytoskeleton, and intracellular calcium dependent and required for host cell invasion.Infection and immunity · 2004Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
The present study addresses the cloning and characterization of a Cryptosporidium parvum antigen, CP2. Sequencing of cDNA and genomic clones revealed a novel gene capable of coding a message of 2,136 nucleotides flanked by 28 and 140 nucleotides of the 5'- and 3'-noncoding regions, respectively. The deduced amino acid sequence suggests that CP2 is a secreted and/or membrane protein. Immunofluorescence microscopy detected CP2 enrichment in sporozoites that subsequently appeared to encase type I meronts in infected HCT-8 cells. Immunogold electron microscopy revealed that CP2 consistently localized to membranous structures throughout development. In addition, progression from macrogametocyte to sporulated oocyst revealed CP2 initially at the periphery of amylopectin-like granules, in the cytoplasm and discrete vesicles, the parasitophorous vacuole, on the surface of sporozoites, and finally on the parasitophorous vacuole membrane (PVM). The observed expression pattern suggests that CP2 may be involved in the invasion process and/or PVM integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.